Neuland Laboratories has announced a robust performance for the first quarter of FY27 (ended June 30, 2026). The company reported a significant 16.3% increase in total income to ₹650.1 crore, primarily driven by its Commercial Manufacturing Services (CMS) projects. Profit after tax witnessed a substantial surge of over 900% to ₹147.4 crore, translating to an Earnings Per Share of ₹114.9.
Neuland Laboratories Reports Strong Q1 FY27 Performance
Neuland Laboratories Limited has disclosed its financial results for the first quarter of Fiscal Year 2027, ended June 30, 2026, revealing a period of substantial growth. The company’s total income rose by 16.3% to ₹650.1 crore, a notable increase from ₹300.6 crore in the corresponding quarter of the previous year. This revenue growth was significantly bolstered by the contribution of its Commercial Manufacturing Services (CMS) projects, which served as the primary drivers of the quarter’s performance.
Profitability and Margin Expansion
The company’s profitability saw a dramatic improvement, with EBITDA reaching ₹231.1 crore, corresponding to an EBITDA margin of 35.5%. This enhanced profitability was attributed to the higher revenue base, effective operating leverage, and a favorable customer mix. The gross margin also expanded to 61.2% from 55.3% in Q1 FY26. Most strikingly, Profit After Tax (PAT) surged to ₹147.4 crore compared to ₹13.7 crore in the prior year’s quarter, resulting in an Earnings Per Share (EPS) of ₹114.9.
Operational Highlights and Investments
A key operational highlight was the improvement in working capital efficiency, with working capital days reducing from 137 days at the end of FY26 to 84 days in FY27. The company also approved capital investments of approximately ₹203 crore, with a substantial portion earmarked for strategic growth initiatives and capacity expansion at Unit 1. Furthermore, Neuland highlighted its strategic collaboration with Gland Pharma for sterile API manufacturing, emphasizing an asset-light approach and its focus on niche generic categories.
Business Outlook and Strategy
Looking ahead, Neuland Laboratories anticipates FY27 to be a year of growth, underpinned by disciplined financial management and operational excellence. The company is focusing on building differentiated products, expanding its presence in key markets, and strengthening its position as a long-term strategic partner to its customers. The company’s strategy involves continued investment in manufacturing infrastructure, R&D, peptides, and complex molecules to maintain its competitive edge and capitalize on emerging market opportunities.
Source: BSE
